Medtronic Says Data from Corevalue Demonstrates Positive Outcomes

Medtronic, Inc. (NYSE: MDT) today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve System delivered through the direct aortic implantation approach. Data presented at the Society of Thoracic Surgeons 48th Annual Meeting demonstrate positive outcomes when the CoreValve System is implanted using the direct aortic approach, which received CE Mark in November 2011. The direct aortic approach is also being evaluated in the Medtronic CoreValve U.S. Pivotal Trial.

Data presented during a late-breaking session showed procedural success in 92 of 93 patients treated at 12 centers across Europe. There were no procedural deaths, the overall 30-day mortality rate was 9.7 percent, and with experience (after three cases) the 30-day mortality rate was 7.0 percent.